zFree

Recent Bottom-Pickers in OIL Got an Early Lump of COAL Instead

Insights - Investors who tried to time a bottom in oil over the last few months got an early lump of coal in their stockings. U.S. and Brent crude both plunged to new lows this week, taking the markets along for the ride. And, next week the Federal Reserve meets to lay out their latest plans for short-term interest rates. While a hike this month is largely expected by market participants, it's the clip at which interest rates will rise over the next few years that has investors on edge.

Read Now

First Hint of What’s to Come With Sarepta and BioMarin

Insights - The event of the week - some would argue the event of the year - was the release of FDA briefing documents related to BioMarin's (BMRN) drisapersen, which faces an FDA advisory committee meeting this coming Tuesday. The drug is up for approval in Duchenne Muscular Dystrophy next month, and the upcoming committee meeting is all about FDA getting input from outside experts on the risk/benefit of approving drisapersen for DMD patients amenable to treatment by exon 51 skipping, drisapersen's mechanism of action.

Read Now

Neurocrine Chalks Up a Win With Latest Clinical Trial

Insights - Teva Pharmaceuticals (TEVA) purchased Auspex Pharmaceuticals this spring for $3.5 billion, primarily for access to the developmental SD-809 (deutetrabenazine), which was in mid-stage studies for the treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. But the larger pharma company has a competitor nipping at its heels.

Read Now